Price History

Hover for the daily close. The dotted line marks the period open.

Compare EVAX with… →

EVAX Key Statistics

As of Sep 4, 2026

Trading

Open: $3.12
Previous Close: $3.08
Day's Range: 3.06–3.16
52-Week Range: 2.71–12.15
Volume: 38.30K
Beta: 0.27

Valuation

Market Cap: $28.15M
P/E Ratio: unprofitable
P/S ratio: 3.76
EPS (ttm): −0.50

Financials (FY)

Revenue (FY): $7.53M+125.12%
Net Income (FY): −$7.71M
Profit margin: −115.54%
Shares Outstanding: 9.02M
1-Year Return: +15.77%

Dividend and dates

Avg Volume: 199.32K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

EVAX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−55.31%−59.84%−61.35%−87.68%+12.90%−34.59%

2021*20222023202420252026*

Year	Return
2026 (partial year)	−34.59%
2025	+12.90%
2024	−87.68%
2023	−61.35%
2022	−59.84%
2021 (partial year)	−55.31%

As of September 4, 2026.

EVAX Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$7.53M	−$7.71M	−102.4%
2024	$3.34M	−$10.57M	−316.0%
2023	$73.00K	−$22.13M	−30308.2%
2022	$0.00	−$23.17M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$7.53M	—	−$9.23M	−$7.71M	−102.4%
2024	$3.34M	—	−$14.73M	−$10.57M	−316.0%
2023	$73.00K	—	−$22.20M	−$22.13M	−30308.2%
2022	$0.00	—	−$25.26M	−$23.17M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

EVAX Valuation vs Biotechnology Median

Median of 656 stocks

Metric	EVAX	Biotechnology median	vs median
P/S ratio	3.76	15.26	0.2x the median
Profit margin	−115.54%	0.00%	115.5 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Evaxion A/S (EVAX) carries a market capitalisation of $28.15M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 46.

EVAX last closed at $3.12 on September 4, 2026. That is +$0.04 (+1.30%) against the previous close. Over the past 52 weeks the price has ranged from $2.71 to $12.15. The latest close sits 15.17% above that 52-week low.

Financial Health

In fiscal 2025, Evaxion A/S reported revenue of $7.53M. That is +125.12% against the prior fiscal year, when revenue was $3.34M. The same year closed with a net loss of $7.71M. The reported profit margin is −115.54%. That is 115.5 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −0.5.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $7.53M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 3.76. On price-to-sales that is 0.2 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.27. Daily returns over the trailing 5 years annualize to a volatility of 129.86%. Over the trailing twelve months the price has returned +15.77%. Across 5 years the annualized return works out at −62.31%.

Growth & Income

No dividend is on file for EVAX.

So far in 2026 the price is −34.59%. The strongest complete calendar year on file is 2025 at +12.90%; the weakest is 2024 at −87.68%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

Evaxion A/S (EVAX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Evaxion A/S	EVAX	$28.15M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Evaxion A/S has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Evaxion A/S

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Visit website →

Evaxion A/S (EVAX) Stock Analysis